Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Aptevo Therapeutics Inc.APVO · Entity 8337 | Director · President and CEO | August 06, 2026 | August 11, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Aptevo Therapeutics Inc.
Report date August 06, 2026 · Filed August 11, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 961 |
Reported balance
After 2026-08-06 transaction · row 1
1 source rowRow 1 · 2026-08-06 · Exercise / conversion · Acquired 961 · Balance 961 F1: Restricted Stock Units ("RSUs") convert into common stock, $0.001 par value per share, of the Issuer on a one-for-one basis. |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2026-08-06 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-08-06 · Exercise / conversion · Disposed 961 · Balance 0 F1: Restricted Stock Units ("RSUs") convert into common stock, $0.001 par value per share, of the Issuer on a one-for-one basis. F2: On August 6, 2025, the reporting person was granted 17,300 (961 post-split) RSUs, vesting on the first anniversary of the date of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: Restricted Stock Units ("RSUs") convert into common stock, $0.001 par value per share, of the Issuer on a one-for-one basis.
F2: On August 6, 2025, the reporting person was granted 17,300 (961 post-split) RSUs, vesting on the first anniversary of the date of grant.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 01, 2019 Filed Mar 5, 2019 02:05 UTC | Aptevo Therapeutics Inc. APVO · Entity 8337 | Exercise / conversionRestricted Stock Unit · Derivative | 7,318 | $0.00 | $0.00 |
DisclosureSEC source: 0001019056-19-000178 · lamothe.xml · derivative · entry 4 Lamothe Jeffrey G. · CIK 0001679967 · SVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,318 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units (the "RSUs") convert into shares of the Issuer's common stock on a one-for-one basis. F3 · derivative.exercise_date: The RSUs were originally issued by Emergent BioSolutions, Inc. ("Emergent") on March 1, 2016. As a result of the spin-off of the Issuer from Emergent effective on August 1, 2016 (the "Spin-off"), each RSU was adjusted and assumed by the Issuer. 7,320 shares of common stock underlying the RSUs vested on each of March 1, 2017 and March 1, 2018, and the remaining 7,318 shares vested on March 1, 2019. F3 · derivative.expiration_date: The RSUs were originally issued by Emergent BioSolutions, Inc. ("Emergent") on March 1, 2016. As a result of the spin-off of the Issuer from Emergent effective on August 1, 2016 (the "Spin-off"), each RSU was adjusted and assumed by the Issuer. 7,320 shares of common stock underlying the RSUs vested on each of March 1, 2017 and March 1, 2018, and the remaining 7,318 shares vested on March 1, 2019. Read SEC document |
| March 01, 2019 Filed Mar 5, 2019 02:05 UTC | Aptevo Therapeutics Inc. APVO · Entity 8337 | Tax withholdingCommon Stock | 2,170 | $1.57 | $3,406.90 |
DisclosureSEC source: 0001019056-19-000178 · lamothe.xml · nonDerivative · entry 2 Lamothe Jeffrey G. · CIK 0001679967 · SVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,024 Read SEC document |
| March 01, 2019 Filed Mar 5, 2019 02:05 UTC | Aptevo Therapeutics Inc. APVO · Entity 8337 | Exercise / conversionCommon Stock | 7,318 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001019056-19-000178 · lamothe.xml · nonDerivative · entry 1 Lamothe Jeffrey G. · CIK 0001679967 · SVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,194 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units (the "RSUs") convert into shares of the Issuer's common stock on a one-for-one basis. Read SEC document |
| February 28, 2019 Filed Mar 5, 2019 02:05 UTC | Aptevo Therapeutics Inc. APVO · Entity 8337 | GrantStock Option (right to buy) · Derivative | 67,400 | $0.00 Strike: $1.52 | $0.00 |
DisclosureSEC source: 0001019056-19-000178 · lamothe.xml · derivative · entry 3 Lamothe Jeffrey G. · CIK 0001679967 · SVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,400 Underlying: Common Stock · 67,400 shares Expires 2029-02-28 F2 · derivative.exercise_date: The option vests in three approximately equal annual installments beginning on February 28, 2020. Read SEC document |
| March 10, 2018 Filed Mar 14, 2018 01:37 UTC | Aptevo Therapeutics Inc. APVO · Entity 8337 | Exercise / conversionRestricted Stock Unit · Derivative | 6,747 | $0.00 | $0.00 |
DisclosureSEC source: 0001019056-18-000435 · lamothe_4.xml · derivative · entry 4 Lamothe Jeffrey G. · CIK 0001679967 · SVP, CFO and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,318 Underlying: Common Stock · 6,747 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each RSU converts into the Issuer's common stock on a one-for-one basis. F3 · derivative.exercise_date: The RSUs were originally issued by Emergent BioSolutions, Inc. ("Emergent") on March 10, 2015. As a result of the spin-off of the Issuer from Emergent effective on August 1, 2016, each RSU was adjusted and assumed by the Issuer. The RSUs fully vested as of March 10, 2018. F3 · derivative.expiration_date: The RSUs were originally issued by Emergent BioSolutions, Inc. ("Emergent") on March 10, 2015. As a result of the spin-off of the Issuer from Emergent effective on August 1, 2016, each RSU was adjusted and assumed by the Issuer. The RSUs fully vested as of March 10, 2018. Read SEC document |
| March 10, 2018 Filed Mar 14, 2018 01:37 UTC | Aptevo Therapeutics Inc. APVO · Entity 8337 | Tax withholdingCommon Stock | 1,583 | $3.13 | $4,954.79 |
DisclosureSEC source: 0001019056-18-000435 · lamothe_4.xml · nonDerivative · entry 2 Lamothe Jeffrey G. · CIK 0001679967 · SVP, CFO and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,876 Read SEC document |
| March 10, 2018 Filed Mar 14, 2018 01:37 UTC | Aptevo Therapeutics Inc. APVO · Entity 8337 | Exercise / conversionCommon Stock | 6,747 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001019056-18-000435 · lamothe_4.xml · nonDerivative · entry 1 Lamothe Jeffrey G. · CIK 0001679967 · SVP, CFO and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,459 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each RSU converts into the Issuer's common stock on a one-for-one basis. Read SEC document |
| March 09, 2018 Filed Mar 14, 2018 01:37 UTC | Aptevo Therapeutics Inc. APVO · Entity 8337 | GrantEmployee Stock Options (Right to Buy) · Derivative | 67,400 | $0.00 Strike: $3.13 | $0.00 |
DisclosureSEC source: 0001019056-18-000435 · lamothe_4.xml · derivative · entry 3 Lamothe Jeffrey G. · CIK 0001679967 · SVP, CFO and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,400 Underlying: Common Stock · 67,400 shares Expires 2028-03-09 F2 · derivative.exercise_date: On March 9, 2018, the reporting person was granted 67,400 stock options vesting in three equal annual installments beginning on the first anniversary of the grant date. Read SEC document |
| March 01, 2018 Filed Mar 6, 2018 00:38 UTC | Aptevo Therapeutics Inc. APVO · Entity 8337 | Exercise / conversionRestricted Stock Unit · Derivative | 7,320 | $0.00 | $0.00 |
DisclosureSEC source: 0001019056-18-000418 · lamothe_4.xml · derivative · entry 3 Lamothe Jeffrey G. · CIK 0001679967 · SVP, CFO and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,065 Underlying: Common Stock · 7,320 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each RSU converts into the Issuer's common stock on a one-for-one basis. F2 · derivative.exercise_date: The RSUs were originally issued by Emergent BioSolutions, Inc. ("Emergent") on March 1, 2016. As a result of the spin-off of the Issuer from Emergent effective on August 1, 2016 (the "Spin-off"), each RSU was adjusted and assumed by the Issuer. The RSUs vest as follows: 7,320 on March 1, 2017, 7,320 on March 1, 2018 and 7,318 on March 1, 2019. F2 · derivative.expiration_date: The RSUs were originally issued by Emergent BioSolutions, Inc. ("Emergent") on March 1, 2016. As a result of the spin-off of the Issuer from Emergent effective on August 1, 2016 (the "Spin-off"), each RSU was adjusted and assumed by the Issuer. The RSUs vest as follows: 7,320 on March 1, 2017, 7,320 on March 1, 2018 and 7,318 on March 1, 2019. Read SEC document |
| March 01, 2018 Filed Mar 6, 2018 00:38 UTC | Aptevo Therapeutics Inc. APVO · Entity 8337 | Tax withholdingCommon Stock | 1,717 | $3.04 | $5,219.68 |
DisclosureSEC source: 0001019056-18-000418 · lamothe_4.xml · nonDerivative · entry 2 Lamothe Jeffrey G. · CIK 0001679967 · SVP, CFO and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,712 Read SEC document |
| March 01, 2018 Filed Mar 6, 2018 00:38 UTC | Aptevo Therapeutics Inc. APVO · Entity 8337 | Exercise / conversionCommon Stock | 7,320 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001019056-18-000418 · lamothe_4.xml · nonDerivative · entry 1 Lamothe Jeffrey G. · CIK 0001679967 · SVP, CFO and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,429 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each RSU converts into the Issuer's common stock on a one-for-one basis. Read SEC document |
| February 03, 2018 Filed Feb 7, 2018 00:21 UTC | Aptevo Therapeutics Inc. APVO · Entity 8337 | Exercise / conversionRestricted Stock Unit · Derivative | 25,340 | $0.00 | $0.00 |
DisclosureSEC source: 0001019056-18-000287 · lamothe_4.xml · derivative · entry 3 Lamothe Jeffrey G. · CIK 0001679967 · SVP, CFO and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,385 Underlying: Common Stock · 25,340 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each RSU converts into the Issuer's common stock on a one-for-one basis. F2 · derivative.exercise_date: On August 3, 2016, the reporting person was granted 50,680 RSUs, vesting in two equal installments on February 3, 2017 and February 3, 2018. F2 · derivative.expiration_date: On August 3, 2016, the reporting person was granted 50,680 RSUs, vesting in two equal installments on February 3, 2017 and February 3, 2018. Read SEC document |
| February 03, 2018 Filed Feb 7, 2018 00:21 UTC | Aptevo Therapeutics Inc. APVO · Entity 8337 | Tax withholdingCommon Stock | 7,514 | $3.24 | $24,345.36 |
DisclosureSEC source: 0001019056-18-000287 · lamothe_4.xml · nonDerivative · entry 2 Lamothe Jeffrey G. · CIK 0001679967 · SVP, CFO and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,109 Read SEC document |
| February 03, 2018 Filed Feb 7, 2018 00:21 UTC | Aptevo Therapeutics Inc. APVO · Entity 8337 | Exercise / conversionCommon Stock | 25,340 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001019056-18-000287 · lamothe_4.xml · nonDerivative · entry 1 Lamothe Jeffrey G. · CIK 0001679967 · SVP, CFO and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,623 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each RSU converts into the Issuer's common stock on a one-for-one basis. Read SEC document |
| June 01, 2017 Filed Jun 2, 2017 01:39 UTC | Aptevo Therapeutics Inc. APVO · Entity 8337 | GrantEmployee Stock Option (right to buy) · Derivative | 33,700 | $0.00 Strike: $2.15 | $0.00 |
DisclosureSEC source: 0001019056-17-000547 · lamothe_4.xml · derivative · entry 1 Lamothe Jeffrey G. · CIK 0001679967 · SVP, CFO and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,700 Underlying: Common Stock · 33,700 shares Expires 2027-05-31 F1 · date: The option grant was approved by a committee of Aptevo Therapeutics Inc.'s board of directors on February 22, 2017, subject to stockholder approval of the Amended and Restated 2016 Stock Incentive Plan (the "Plan") under which the option was granted. Aptevo Therapeutics Inc.'s stockholders approved the Plan on May 31, 2017. F2 · derivative.exercise_date: The option vests in three equal annual installments beginning on June 1, 2018. Read SEC document |
| March 10, 2017 Filed Mar 14, 2017 01:05 UTC | Aptevo Therapeutics Inc. APVO · Entity 8337 | Exercise / conversionRestricted Stock Unit · Derivative | 18,863 | $0.00 | $0.00 |
DisclosureSEC source: 0001019056-17-000288 · lamothe_4.xml · derivative · entry 9 Lamothe Jeffrey G. · CIK 0001679967 · SVP, CFO and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,725 Underlying: Common Stock · 18,863 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each RSU converts into the Issuer's common stock on a one-for-one basis. F4 · derivative.exercise_date: The RSUs were originally issued by Emergent on March 11, 2014 and, as a result of the Spin-off, were adjusted and assumed by the Issuer. The RSUs fully vested on March 10, 2017. F4 · derivative.expiration_date: The RSUs were originally issued by Emergent on March 11, 2014 and, as a result of the Spin-off, were adjusted and assumed by the Issuer. The RSUs fully vested on March 10, 2017. Read SEC document |
| March 10, 2017 Filed Mar 14, 2017 01:05 UTC | Aptevo Therapeutics Inc. APVO · Entity 8337 | Exercise / conversionRestricted Stock Unit · Derivative | 6,746 | $0.00 | $0.00 |
DisclosureSEC source: 0001019056-17-000288 · lamothe_4.xml · derivative · entry 8 Lamothe Jeffrey G. · CIK 0001679967 · SVP, CFO and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,588 Underlying: Common Stock · 6,746 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each RSU converts into the Issuer's common stock on a one-for-one basis. F3 · derivative.exercise_date: The RSUs were originally issued by Emergent on March 10, 2015 and, as a result of the Spin-off, were adjusted and assumed by the Issuer. The RSUs vest as follows: 6,746 on March 10, 2017 and 6,747 on March 10, 2018. F3 · derivative.expiration_date: The RSUs were originally issued by Emergent on March 10, 2015 and, as a result of the Spin-off, were adjusted and assumed by the Issuer. The RSUs vest as follows: 6,746 on March 10, 2017 and 6,747 on March 10, 2018. Read SEC document |
| March 10, 2017 Filed Mar 14, 2017 01:05 UTC | Aptevo Therapeutics Inc. APVO · Entity 8337 | Tax withholdingCommon Stock | 4,990 | $1.78 | $8,882.20 |
DisclosureSEC source: 0001019056-17-000288 · lamothe_4.xml · nonDerivative · entry 6 Lamothe Jeffrey G. · CIK 0001679967 · SVP, CFO and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,284 Read SEC document |
| March 10, 2017 Filed Mar 14, 2017 01:05 UTC | Aptevo Therapeutics Inc. APVO · Entity 8337 | Exercise / conversionCommon Stock | 18,863 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001019056-17-000288 · lamothe_4.xml · nonDerivative · entry 5 Lamothe Jeffrey G. · CIK 0001679967 · SVP, CFO and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,274 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each RSU converts into the Issuer's common stock on a one-for-one basis. Read SEC document |
| March 10, 2017 Filed Mar 14, 2017 01:05 UTC | Aptevo Therapeutics Inc. APVO · Entity 8337 | Tax withholdingCommon Stock | 1,785 | $1.78 | $3,177.30 |
DisclosureSEC source: 0001019056-17-000288 · lamothe_4.xml · nonDerivative · entry 4 Lamothe Jeffrey G. · CIK 0001679967 · SVP, CFO and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,411 Read SEC document |
| March 01, 2017 Filed Mar 14, 2017 01:05 UTC | Aptevo Therapeutics Inc. APVO · Entity 8337 | Exercise / conversionRestricted Stock Unit · Derivative | 7,320 | $0.00 | $0.00 |
DisclosureSEC source: 0001019056-17-000288 · lamothe_4.xml · derivative · entry 7 Lamothe Jeffrey G. · CIK 0001679967 · SVP, CFO and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,334 Underlying: Common Stock · 7,320 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each RSU converts into the Issuer's common stock on a one-for-one basis. F2 · derivative.exercise_date: The RSUs were originally issued by Emergent BioSolutions, Inc. ("Emergent") on March 1, 2016. As a result of the spin-off of the Issuer from Emergent effective on August 1, 2016 (the "Spin-off"), each RSU was adjusted and assumed by the Issuer. The RSUs vest as follows: 7,320 on March 1, 2017, 7,320 on March 1, 2018 and 7,318 on March 1, 2019. F2 · derivative.expiration_date: The RSUs were originally issued by Emergent BioSolutions, Inc. ("Emergent") on March 1, 2016. As a result of the spin-off of the Issuer from Emergent effective on August 1, 2016 (the "Spin-off"), each RSU was adjusted and assumed by the Issuer. The RSUs vest as follows: 7,320 on March 1, 2017, 7,320 on March 1, 2018 and 7,318 on March 1, 2019. Read SEC document |
| March 01, 2017 Filed Mar 14, 2017 01:05 UTC | Aptevo Therapeutics Inc. APVO · Entity 8337 | Exercise / conversionCommon Stock | 6,746 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001019056-17-000288 · lamothe_4.xml · nonDerivative · entry 3 Lamothe Jeffrey G. · CIK 0001679967 · SVP, CFO and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,196 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each RSU converts into the Issuer's common stock on a one-for-one basis. Read SEC document |
| March 01, 2017 Filed Mar 14, 2017 01:05 UTC | Aptevo Therapeutics Inc. APVO · Entity 8337 | Tax withholdingCommon Stock | 1,936 | $2.02 | $3,910.72 |
DisclosureSEC source: 0001019056-17-000288 · lamothe_4.xml · nonDerivative · entry 2 Lamothe Jeffrey G. · CIK 0001679967 · SVP, CFO and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,450 Read SEC document |
| March 01, 2017 Filed Mar 14, 2017 01:05 UTC | Aptevo Therapeutics Inc. APVO · Entity 8337 | Exercise / conversionCommon Stock | 7,320 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001019056-17-000288 · lamothe_4.xml · nonDerivative · entry 1 Lamothe Jeffrey G. · CIK 0001679967 · SVP, CFO and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,386 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each RSU converts into the Issuer's common stock on a one-for-one basis. Read SEC document |
| February 24, 2017 Filed Feb 27, 2017 21:03 UTC | Aptevo Therapeutics Inc. APVO · Entity 8337 | GrantStock Option (right to buy) · Derivative | 33,700 | $0.00 Strike: $1.96 | $0.00 |
DisclosureSEC source: 0001019056-17-000234 · lamothe_4.xml · derivative · entry 1 Lamothe Jeffrey G. · CIK 0001679967 · SVP, CFO and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 142,232 Underlying: Common Stock · 33,700 shares Expires 2027-02-24 F1 · derivative.exercise_date: The options vest in three equal annual installments beginning on February 24, 2018. Read SEC document |
| February 03, 2017 Filed Feb 8, 2017 23:28 UTC | Aptevo Therapeutics Inc. APVO · Entity 8337 | Exercise / conversionRestricted Stock Unit · Derivative | 25,340 | $0.00 | $0.00 |
DisclosureSEC source: 0001019056-17-000111 · lamothe_4.xml · derivative · entry 3 Lamothe Jeffrey G. · CIK 0001679967 · SVP, CFO and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 79,654 Underlying: Common Stock · 25,340 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each RSU converts into the Issuer's common stock on a one-for-one basis. F2 · derivative.exercise_date: On August 3, 2016, the reporting person was granted 50,680 RSUs, vesting in two equal installments on February 3, 2017 and February 3, 2018. F2 · derivative.expiration_date: On August 3, 2016, the reporting person was granted 50,680 RSUs, vesting in two equal installments on February 3, 2017 and February 3, 2018. Read SEC document |
| February 03, 2017 Filed Feb 8, 2017 23:28 UTC | Aptevo Therapeutics Inc. APVO · Entity 8337 | Tax withholdingCommon Stock | 8,274 | $1.92 | $15,886.08 |
DisclosureSEC source: 0001019056-17-000111 · lamothe_4.xml · nonDerivative · entry 2 Lamothe Jeffrey G. · CIK 0001679967 · SVP, CFO and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,066 Read SEC document |
| February 03, 2017 Filed Feb 8, 2017 23:28 UTC | Aptevo Therapeutics Inc. APVO · Entity 8337 | Exercise / conversionCommon Stock | 25,340 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001019056-17-000111 · lamothe_4.xml · nonDerivative · entry 1 Lamothe Jeffrey G. · CIK 0001679967 · SVP, CFO and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,340 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each RSU converts into the Issuer's common stock on a one-for-one basis. Read SEC document |
| August 03, 2016 Filed Sep 27, 2016 19:42 UTC Amendment | Aptevo Therapeutics Inc. APVO · Entity 8337 | GrantRestricted Stock Unit · Derivative | 50,680 | $0.00 | $0.00 |
DisclosureSEC source: 0001019056-16-001557 · lamothe_4a.xml · derivative · entry 2 Lamothe Jeffrey G. · CIK 0001679967 · SVP, CFO and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 104,994 Underlying: Common Stock · 50,680 shares Expires not disclosed F2 · derivative.exercise_price: Each RSU represents the right of the reporting person to receive one share of common stock of the Issuer. F3 · derivative.exercise_date: This report has been amended to reflect that the RSUs will vest in two equal installments on February 3, 2017 and February 3, 2018. F3 · derivative.expiration_date: This report has been amended to reflect that the RSUs will vest in two equal installments on February 3, 2017 and February 3, 2018. F4 · balance_after: This report has been amended to reflect the 35,451 RSUs that were originally issued by Emergent BioSolutions, Inc. ("Emergent") and, as a result of the spin-off of the Issuer from Emergent effective on August 1, 2016, were adjusted and assumed by the Issuer under its Converted Equity Awards Incentive Plan. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.